MINNEAPOLIS , Oct. 30, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the first quarter ended September 30, 2024 . First Quarter FY2025 Highlights First quarter organic revenue increased by 4% (5% reported) to $289.5 million . GAAP earnings per share (EPS) was $0.21 versus $0.31 one year ago. Delivered adjusted EPS of $0.42 compared to $0.41 one year ago. Continued... Read More

MINNEAPOLIS , Oct. 30, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended September 30, 2024 . The quarterly dividend will be payable November 22, 2024 , to all common shareholders of record on November 11, 2024 . Future cash dividends will be considered by the Board of Directors on a quarterly basis.... Read More

ST. PAUL, Minn. , Oct. 29, 2024 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing and Bio-Techne Corporation (NASDAQ: TECH), today announced that Luminary Therapeutics has been awarded a $300,000 G-Rex® Grant. Luminary's G-Rex® Grant will enable expeditious process development and IND-enabling studies of several novel CAR γδ T cell therapies that will be evaluated in Phase 1 clinical trials for the... Read More

MINNEAPOLIS , Oct. 10, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Wednesday, October 30, 2024 , at 8:00 a.m. CDT to review its first quarter fiscal 2025 financial results. Access to the discussion may be obtained as follows: Time: 8:00 a.m. CDT Date: October 30, 2024 Dial-in: 1-877-407-9208 or 1-201-493-6784 (for international callers)... Read More

Award will support clinical manufacturing of the Company's promising Neutrophil only Leukocyte Infusion Therapy (N-LIfT) platform ST. PAUL, Minn. , Oct. 9, 2024 /PRNewswire/ -- ScaleReady ™ , in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH) and CellReady ™ , and LIfT BioSciences, ('LIfT' or 'the Company'), a rapidly emerging biotech company about to start clinical trials for its... Read More

ST. PAUL, Minn. , Oct. 8, 2024 /PRNewswire/ -- ScaleReady™, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH) and CellReady™, today announced that Eric Tran , Ph.D, Associate Member of the Earle A. Chiles Research Institute, a division of the Providence Cancer Institute, has been awarded a G-Rex Grant. Dr. Tran's $200,000 G-Rex Grant will enable process development and IND enabling... Read More

ST. PAUL, Minn. , Oct. 7, 2024 /PRNewswire/ -- ScaleReady™, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH) and CellReady™, today announced that Christopher A. Klebanoff , MD, a physician-scientist at Memorial Sloan Kettering Cancer Center (MSK) has been awarded a G-Rex ® Grant. Dr. Klebanoff's $300,000 G-Rex ® Grant will provide enabling reagents to facilitate process development,... Read More

MINNEAPOLIS , Sept. 26, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that one of its spatial biology brands, Lunaphore , is partnering with Discovery Life Sciences (Discovery) to add Lunaphore COMET™ , a best-in-class spatial biology platform, to Discovery's global suite of biospecimen products and specialty lab services supporting customers with clinical research. The strategic partnership... Read More

MINNEAPOLIS , Sept. 24, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced it will showcase its portfolio of solutions advancing neuroscience research at the upcoming annual meeting of the Society for Neuroscience (SfN) at Neuroscience 2024, taking place October 5-9, 2024 , in Chicago, Illinois . At booth #1165, Bio-Techne will feature its market-leading portfolio of high-quality life science... Read More

MINNEAPOLIS , Sept. 18, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today issued its 2024 Corporate Sustainability Report (CSR), detailing the continued progress advancing its Environmental, Social and Governance (ESG) initiatives. Bio-Techne's CSR is organized around four key pillars: Our People, Advancing Science, Governance and Operational Integrity, and The Environment. Bio-Techne's EPIC values... Read More

ST. PAUL, Minn. , Sept. 18, 2024 /PRNewswire/ -- ScaleReady™, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH) and CellReady™, today announced that ImmunoScape Pte. Ltd. (a Singapore-U.S. based TCR-T therapy company) has been awarded a G-Rex ® Grant. ImmunoScape's $250,000 G-Rex ® Grant will enable process development and IND enabling studies of their novel WT1-targeted TCR-T cell... Read More

ST. PAUL, Minn. , Sept. 17, 2024 /PRNewswire/ -- ScaleReady TM , in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH), and CellReady TM , today announced that it has awarded a $150,000 G-Rex Grant to Verismo Therapeutics , a clinical-stage CAR T company developing the novel KIR-CAR platform technology. This grant will support Verismo Therapeutics' ongoing efforts to optimize the development... Read More

PHILADELPHIA , Sept. 17, 2024 /PRNewswire/ -- Verismo Therapeutics , a clinical-stage CAR T company developing the novel KIR-CAR platform technology, today announced that it has been awarded a $150,000 G-Rex Grant by ScaleReady™. This grant will support Verismo Therapeutics' ongoing efforts to optimize the development and manufacturing of its KIR-CAR platform using the G-Rex. The G-Rex Grant is part of ScaleReady's $20... Read More

ST. PAUL, Minn. , Sept. 16, 2024 /PRNewswire/ -- ScaleReady and Bio-Techne Corporation (NASDAQ: TECH) today announced the launch of the G-Rex optimized ProPak TM GMP Cytokines, ideally tailored to high efficiency closed system cell and gene-modified cell therapy (CGT) manufacturing. The ProPak TM GMP Cytokine product consists of a weldable bag filled with liquid formulated GMP-grade cytokines, specifically interleukin-7... Read More

ST. PAUL, Minn. , Aug. 27, 2024 /PRNewswire/ -- ScaleReady™, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH) and CellReady™, today announced that Dr. Steve Feldman , Scientific Director and Site Head of Stanford Medicine's Laboratory for Cell and Gene Medicine (LCGM), has been awarded the inaugural G-Rex® Grant. Dr. Feldman's $300,000 G-Rex Grant will enable expeditious development of... Read More

MINNEAPOLIS , Aug. 26, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman , President and Chief Executive Officer will present at the following investor conferences: Morgan Stanley 22 nd Annual Global Healthcare Conference September 4, 2024 4:05 PM EDT 2024 Wells Fargo Healthcare Conference September 6, 2024 11:00 AM EDT Baird 2024 Global Healthcare Conference September 10, 2024... Read More

MINNEAPOLIS , Aug. 7, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended June 30, 2024 . The quarterly dividend will be payable August 30, 2024 , to all common shareholders of record on August 19, 2024 . Future cash dividends will be considered by the Board of Directors on a quarterly basis. Bio-Techne... Read More

MINNEAPOLIS , Aug. 7, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the fourth quarter ending June 30, 2024 . Fourth Quarter FY2024 Highlights Fourth quarter organic revenue increased by 1% (2% reported) to $306.1 million . Full year organic revenue increased 1% (2% reported) to $1.2 billion . GAAP earnings per share (EPS) was $0.25 versus $0.47 one year ago. Delivered... Read More

MINNEAPOLIS , July 31, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) is pleased to announce the launch of the Leo™ System. This next-generation Simple Western™ instrument offers higher throughput, flexibility, and efficiency over the current Jess™ and Abby™ Simple Western Systems. This state-of-the-art instrument enables simultaneous processing of up to 100 samples in a single 3-hour run, allowing scientists to... Read More

MINNEAPOLIS , July 29, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced its participation in Spear Bio's $45 million Series A funding round. Spear Bio will use the proceeds from this funding round to further accelerate product development and scale its in-house manufacturing capacity. Bio-Techne joined Foresite Capital, and other investors, in this funding round. Founded in 2021 and headquartered in... Read More

MINNEAPOLIS , July 15, 2024 /PRNewswire/ -- Bio-Techne Corporation ( NASDAQ : TECH) today announced that management will host a conference call and webcast on Wednesday, August 7, 2024 , at 8:00 a.m . CDT to review fourth quarter and fiscal 2024 financial results. Access to the discussion may be obtained as follows: Time: 8:00 a.m. CDT Date: August 7, 2024 Dial-in: 1-800-343-4136 or 1-203-518-9843 (for international callers)... Read More

MINNEAPOLIS , May 31, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman , President and Chief Executive Officer will present at the following investor conferences: William Blair 44 th Annual Growth Conference June 4, 2024 9:20 AM CDT Jefferies Global Healthcare Conference June 6, 2024 9:30 AM EDT Goldman Sachs 45 th Annual Global Healthcare Conference June 11, 2024 9:20 AM EDT A... Read More

MINNEAPOLIS , May 30, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) will showcase multiple applications of its recently launched MauriceFlex™ System at the 72 nd ASMS Conference on Mass Spectrometry and Allied Topics, taking place June 2 nd -6 th in Anaheim, California . The MauriceFlex system is Bio-Techne's latest imaged capillary isoelectric focusing (icIEF) solution, which enables icIEF-based fractionation... Read More

ST. PAUL, Minn. , May 29, 2024 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH) and CellReady, today announced the launch of the G-Rex® Grant Program, a $20 million initiative to propel the advancement of cell and gene therapies (CGT). The G-Rex® Grant Program will provide academic and commercial institutions engaged in IND enabling pre-clinical research,... Read More

MINNEAPOLIS , May 23, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman , President and Chief Executive Officer will present at the 2024 Leerink Partners Healthcare Crossroads Conference on Wednesday, May 29, 2024 , at 8:40 a.m. CDT . A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at... Read More

MINNEAPOLIS , May 22, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) and Regulus Therapeutics Inc., a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced continued technical and clinical collaboration following release of Regulus' positive topline results from the second cohort of patients in its Phase 1b MAD (multiple ascending dose)... Read More

MINNEAPOLIS , May 8, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman , President and Chief Executive Officer, will present at the BofA Securities Health Care Conference on Tuesday, May 14, 2024 , at 2:20 p.m. PDT . A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar... Read More

MINNEAPOLIS , May 7, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced it will showcase its portfolio of cell and gene therapy workflow solutions at the upcoming annual meeting of the American Society of Gene & Cell Therapy (ASGCT), taking place May 7-11, 2024 , in Baltimore, Maryland . Bio-Techne's booth (#1627 ) will feature our market-leading portfolio of high-quality life science research use... Read More

MINNEAPOLIS , May 1, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the third quarter ending March 31, 2024 . Third Quarter FY2024 Highlights Third quarter organic revenue increased by 2% (3% reported) to $303.4 million . GAAP earnings per share (EPS) was $0.31 versus $0.43 one year ago. Delivered adjusted EPS of $0.48 compared to $0.53 one year ago. Strong commercial... Read More

MINNEAPOLIS , May 1, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended March 31, 2024 . The quarterly dividend will be payable May 24, 2024 , to all common shareholders of record on May 13, 2024 . Future cash dividends will be considered by the Board of Directors on a quarterly basis. Bio-Techne Corporation... Read More

MINNEAPOLIS , April 30, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced the appointment of Dr. Judith Klimovsky to serve as an independent director on the Company's Board of Directors, April 24, 2024 . Dr. Klimovsky will serve as a member of the Science and Technology Committee. Following the appointment, the board of Bio-Techne will be temporarily comprised of eleven directors, ten of whom are... Read More

MINNEAPOLIS , April 29, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities is pleased to announce a significant milestone in its commitment to providing cutting-edge solutions to its customers. Effective May 1, 2024 , Bio-Techne will enter into a strategic distribution agreement with... Read More

MINNEAPOLIS , April 26, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) and Novomol-Dx, a molecular diagnostics company, are pleased to announce the development of Bio-Marker Pathfinder (BMP), a first of its kind ocular biomarker kit, as a point-of-care application. Novomol-Dx is a molecular diagnostics company focused on commercializing tests for the diagnosis and treatment of ophthalmic diseases utilizing... Read More

Bio-Techne enforces intellectual property for gold standard RNAscope® ISH technology in spatial biology research and clinical applications. MINNEAPOLIS , April 23, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities, today announced that it has taken legal action in the Unified Patent... Read More

MINNEAPOLIS , April 10, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Wednesday, May 1, 2024 , at 8:00 a.m. CDT to review third quarter fiscal 2024 financial results. Access to the discussion may be obtained as follows: Time: 8:00 a.m. CDT Date: May 1, 2024 Dial-in: 1-877-407-9208 or 1-201-493-6784 (for international callers) Conference... Read More

Advanced Cell Diagnostics (ACD) achieves significant global customer adoption milestone MINNEAPOLIS , April 8, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Advanced Cell Diagnostics (ACD), part of Bio-Techne's Spatial Biology Division, has surpassed 10,000 peer-reviewed publications referencing the use and application of RNAscope ™ ISH technology. Over 50% of these publications were... Read More

MINNEAPOLIS , April 3, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced it will showcase its portfolio of solutions to advance cancer research from target discovery to cell therapy development at the upcoming annual meeting of the American Association for Cancer Research (AACR), taking place April 5-10, 2024 , in San Diego, California . Bio-Techne will showcase its solutions at booth #541 , featuring... Read More

MINNEAPOLIS , April 1, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a leading provider of innovative tools and bioactive reagents for the research and clinical diagnostic communities today announced that its R&D Systems brand has been named "ELISA Kit Supplier of the Year" in CiteAb's prestigious annual industry awards. Additionally, Advanced Cell Diagnostics (ACD), part of Bio-Techne's Spatial Biology... Read More

MINNEAPOLIS , March 28, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) is pleased to announce that Lunaphore , part of Bio-Techne's Spatial Biology Division, is partnering with Nikon Instruments Inc. (Nikon) to expand access to spatial biology services with the COMET™ platform for US-based biotech, pharma, and academic customers. Lunaphore's flagship COMET technology is the only fully-automated, high-throughput,... Read More

The QuantideX ® qPCR BCR-ABL IS Kit is now compliant with the latest diagnostic regulations in Europe MINNEAPOLIS , March 22, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Asuragen, part of Bio-Techne's Molecular Diagnostics Division, has completed the Class C Certification under the new European Union In Vitro Diagnostic Regulation (IVDR) for its QuantideX ® qPCR BCR-ABL IS Kit. Previously,... Read More

MINNEAPOLIS , March 12, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Will Geist , President, Protein Sciences Segment, will present at the KeyBanc Life Sciences & MedTech Investor Forum on Tuesday, March 19, 2024 , at 9:45 a.m. EDT . A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at... Read More

MINNEAPOLIS , March 6, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman , President and Chief Executive Officer, will present at the Barclays 26 th Annual Global Healthcare Conference on Wednesday, March 13, 2024 , at 8:30 a.m. EDT . A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at... Read More

MINNEAPOLIS , Feb. 1, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the second quarter ended December 31, 2023 . Second Quarter FY2024 Highlights Second quarter organic revenue declined by 2% (0% reported) to $272.6 million . Organic revenue remained flat (2% reported) in the first half of fiscal 2024 at $549.5 million . GAAP earnings per share (EPS) was $0.17 versus... Read More

MINNEAPOLIS , Feb. 1, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended December 31, 2023 . The quarterly dividend will be payable February 26, 2024 , to all common shareholders of record on February 12, 2024 . Future cash dividends will be considered by the Board of Directors on a quarterly basis. Bio-Techne... Read More

Advanced Cell Diagnostics (ACD), a Bio-Techne spatial biology brand, achieves technical breakthrough enabling protease-free, same-slide detection of protein and RNA biomarkers using industry-leading RNAscope™ technology. MINNEAPOLIS , Jan. 29, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Advanced Cell Diagnostics (ACD) , a Bio-Techne spatial biology brand, has set a new standard with the... Read More

MINNEAPOLIS , Jan. 25, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that its spatial biology brands, Lunaphore and Advanced Cell Diagnostics (ACD) , will launch the first fully automated spatial multiomics workflow with same-section hyperplex detection of RNA and protein biomarkers. This state-of-the-art solution revolutionizes the field of predictive biomarker research and drug development. The... Read More

MINNEAPOLIS , Jan. 24, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) had the honor of welcoming presentations from leading scientists from two major biopharmaceutical companies, Pfizer and Sanofi, at the WCBP conference held in Washington D.C. The focus of these presentations was on the transformative impact of Bio-Techne's MauriceFlex™ system on their biotherapeutic development processes. MauriceFlex™, known... Read More

MINNEAPOLIS , Jan. 16, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Thursday, February 1, 2024 , at 8:00 a.m. CST to review second quarter fiscal 2024 financial results. Access to the discussion may be obtained as follows: Time: 8:00 a.m. CST Date: February 1, 2024 Dial-in: 1-877-407-9208 or 1-201-493-6784 (for international callers)... Read More

MINNEAPOLIS , Jan. 5, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced Matthew F. McManus has been appointed President, Diagnostics and Genomics Segment, effective January 8, 2024 . Dr. McManus succeeds Kim Kelderman , who will become Bio-Techne's Chief Executive Officer effective February 1, 2024 . Dr. McManus has over two decades of experience as a senior life sciences leader, most recently... Read More

MINNEAPOLIS , Jan. 4, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced it will present its portfolio of products and solutions to enable cell and gene therapy development and manufacturing at Phacilitate's Advanced Therapies Week , taking place January 16-19 at the Miami Beach Convention Center in Miami, Florida . Bio-Techne's booth (#509) will feature its wide range of products, services, and... Read More

MINNEAPOLIS , Dec. 21, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman , current Chief Operating Officer, and Chief Executive Officer effective February 1, 2024 , will present at the 42 nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 , at 9:00 a.m. PST . A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor... Read More

MINNEAPOLIS , Dec. 20, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that it has filed a Drug Master File (DMF) with the U.S. Food and Drug Administration (FDA) for its ExCellerate™ GMP iPSC Expansion Medium, Animal Free ( CCM0036-GMP ), supporting the development and manufacture of regenerative medicine and stem cell therapies. ExCellerate GMP iPSC Expansion Medium is optimized to support robust... Read More

MINNEAPOLIS , Dec. 14, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Lunaphore , a Bio-Techne brand, and SIB Swiss Institute of Bioinformatics , have been awarded Innosuisse funding for an innovation project. The collaboration aims to develop novel AI-based assay development tools for spatial biology on Lunaphore's COMET™ to further accelerate the adoption of multiplex sequential... Read More

MINNEAPOLIS , Nov. 27, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth , President and Chief Executive Officer, and Kim Kelderman , Chief Operating Officer will present at the 6 th Annual Evercore ISI HealthCONx Conference on Wednesday, November 29, 2023 , at 2:10 p.m. EST . A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor... Read More

MINNEAPOLIS , Nov. 13, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that it will present at the following investor conferences: Stifel 2023 Healthcare Conference November 15, 2023 8:35 AM EST Stephens Annual Investment Conference November 15, 2023 3:00 PM EST A live webcast of the presentations can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at... Read More

Kitted assays for clinical laboratories streamline the detection of challenging genes and variants to improve results for underrepresented populations MINNEAPOLIS , Nov. 2, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Asuragen, a Bio-Techne brand, will present new data on clinical laboratory testing solutions related to cystic fibrosis variant detection, cancer monitoring, resolving... Read More

MINNEAPOLIS , Oct. 31, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the first quarter ended September 30, 2023 . First Quarter FY2024 Highlights First quarter organic revenue increased by 2% (3% reported) to $276.9 million . GAAP earnings per share 1) (EPS) was $0.31 versus $0.55 one year ago. Delivered adjusted EPS 1) of $0.41 compared to $0.45 one year ago. Our ExoDx... Read More

MINNEAPOLIS , Oct. 31, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended September 30, 2023 . The quarterly dividend will be payable November 24, 2023 , to all common shareholders of record on November 10, 2023 . Future cash dividends will be considered by the Board of Directors on a quarterly basis.... Read More

MINNEAPOLIS and LAUSANNE, Switzerland , Oct. 25, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Lunaphore , a Bio-Techne brand, will have its technologies featured in several presentations by prominent research centers at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting , taking place in San Diego , November 1-5, 2023 . The recent studies will demonstrate the unmatched... Read More

MINNEAPOLIS , Oct. 19, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that its Board of Directors appointed Kim Kelderman as President and Chief Executive Officer effective February 1, 2024 . Concurrent with his role as CEO, Mr. Kelderman will also become a member of Bio-Techne's Board of Directors. Prior to assuming CEO responsibilities, Mr. Kelderman will become Chief Operating Officer (COO)... Read More

MINNEAPOLIS , Oct. 16, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a leading provider of proteins, antibodies and Immunoassays today announced that its Wallingford, CT facility has received ISO 13485:2023 certification for its quality management system (QMS), demonstrating the company's commitment to producing products for clinical applications. The company's Wallingford site manufacturers Bio-Techne's... Read More

MINNEAPOLIS , Oct. 10, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Tuesday, October 31, 2023 , at 8:00 a.m. CDT to review first quarter fiscal 2024 financial results. Access to the discussion may be obtained as follows: Time: 8:00 a.m. CDT Date: October 31, 2023 Dial-in: 1-877-407-9208 or 1-201-493-6784 (for international callers)... Read More

MINNEAPOLIS , Sept. 28, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Dr. Jordan Laser has received the AMP Meritorious Service Award from the Association for Molecular Pathology (AMP). Dr. Laser is receiving this honor to recognize his dedication and effort behind the scenes to position AMP as the premier molecular diagnostics professional association around the world. Dr. Laser currently... Read More

MINNEAPOLIS , Sept. 27, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) was pleased to host presentations by three industry experts yesterday at the CASSS CE Pharm conference in Philadelphia, PA. These industry experts highlighted how Bio-Techne's ProteinSimple branded Maurice™ and MauriceFlex™ systems improved their therapeutic development workflows. Both systems offer automated capillary isoelectric focusing... Read More

MINNEAPOLIS , Sept. 26, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) is pleased to launch the new Maurice Chromeleon Driver Kit, which enables control of its Maurice™ instrument with the Thermo Scientific™ Chromeleon™ Chromatography Data System (CDS). In addition to Compass for iCE, and Waters™ Empower® CDS, scientists now can use Chromeleon CDS to analyze protein charge and size data generated from the Maurice... Read More

MINNEAPOLIS , Sept. 25, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today issued its 2023 Corporate Sustainability Report (CSR), detailing the continued progress advancing its Environmental, Social and Governance (ESG) initiatives. Bio-Techne's CSR is organized around four key pillars: Our People, Advancing Science, Governance and Operational Integrity, and The Environment. Bio-Techne's EPIC values... Read More

LONDON and MINNEAPOLIS , Sept. 19, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) and Cizzle Biotechnology Holdings plc, the UK-based diagnostics developer, are pleased to announce recent progress evaluating specific monoclonal antibodies for Cizzle's CIZ1B cancer biomarker. Cizzle has successfully completed an evaluation programme aimed at assessing the feasibility of using the Simple Western platform from... Read More

MINNEAPOLIS , Aug. 28, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that it will present at the following investor healthcare conferences: 2023 Wells Fargo Healthcare Conference September 6, 2023 10:15 AM EDT Baird 2023 Global Healthcare Conference September 12, 2023 4:55 PM EDT Morgan Stanley 21 st Annual Global Healthcare Conference September 13, 2023 2:55 PM EDT A live webcast of the... Read More

MINNEAPOLIS , Aug. 24, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host its 2023 Investor Day on Friday, September 8, 2023 , starting at 8:30 a.m. EDT . The meeting will take place at the JW Marriott Essex House New York, 160 Central Park South, New York City . The Investor Day will feature presentations from members of Bio-Techne's senior leadership team followed by Q&A.... Read More

MINNEAPOLIS , Aug. 15, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Jim Hippel , Executive Vice President and Chief Financial Officer, will present at the UBS MedTech, Tools and Genomics Summit 2023 on Thursday, August 17, 2023 , at 10:00 a.m. PDT . A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at... Read More

MINNEAPOLIS , Aug. 14, 2023 /PRNewswire/ -- Bio-Techne (NASDAQ: TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities, today announced that the company will end their collaboration with Akoya Biosciences to co-develop an automated RNAscope™ workflow for use with the PhenoCycler®-Fusion System. The decision was made following best efforts... Read More

MINNEAPOLIS , Aug. 8, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the fourth quarter ended June 30, 2023 . Fourth Quarter FY2023 Highlights Fourth quarter organic revenue increased by 5% (5% reported) to $301.3 million . Full year organic revenue increased 5% (3% reported) to $1.1 billion . GAAP earnings per share 1) (EPS) was $0.47 versus $0.38 one year ago. Delivered... Read More

MINNEAPOLIS , Aug. 8, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended June 30, 2023 . The quarterly dividend will be payable September 1, 2023 , to all common shareholders of record on August 18, 2023.... Read More

MINNEAPOLIS , July 13, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Tuesday, August 8, 2023 , at 8:00 a.m. CDT to review fourth quarter and fiscal 2023 financial results. Access to the discussion may be obtained as follows: Time: 8:00 a.m. CDT Date: August 8, 2023 Dial-in: 1-877-300-8521 or 1-412-317-6026 (for international callers)... Read More

MINNEAPOLIS , July 10, 2023 /PRNewswire/ -- Bio-Techne Pharmaceutical (NASDAQ:TECH) today announced it has completed the acquisition of Lunaphore Technologies SA, a leading developer of fully automated spatial biology solutions. Bio-Techne and Lunaphore are combining forces to accelerate their spatial biology leadership position in translational and clinical research markets. Lunaphore's instrument portfolio includes COMET ™... Read More

TOLOCHENAZ, Switzerland & MINNEAPOLIS / Jun 22, 2023 / Business Wire / L unaphore Technologies SA , a Swiss life sciences company developing technology to enable spatial biology in every laboratory, today announced it has reached an agreement to be acquired by Bio-Techne Corporation (NASDAQ:TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic... Read More

MINNEAPOLIS and TOLOCHENAZ, Switzerland , June 22, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities, today announced it has reached an agreement to acquire Lunaphore, Inc. Bio-Techne anticipates the acquisition to close in the first quarter of its fiscal 2024. Founded in 2014 and... Read More

MINNEAPOLIS , June 1, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that it prevailed on a claim that Miltenyi Biotec B.V. & Co. KG commercialized antibodies it developed based on information obtained by reverse engineering Bio-Techne's proprietary R&D Systems branded TIGIT and CCR-7 antibodies. Specifically, the Court held "it has been proven that [Miltenyi's] TIGIT and CCR-7 antibodies are the... Read More

MINNEAPOLIS , May 25, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Jim Hippel , Executive Vice President and Chief Financial Officer, will present at the 2023 Jefferies Healthcare Conference on Thursday, June 8, 2023 , at 12:30 p.m. EDT . A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at... Read More

Halfway through 5-year study, ExoDx Prostate Test offers more accurate stratification of high- and low-risk patients compared to standard of care MINNEAPOLIS , May 18, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Exosome Diagnostics, a Bio-Techne brand, has reported interim results from a previously published prospective, randomized study of more than 1,000 patients aimed at evaluating the... Read More

Enabling Bio-Techne's gold-standard RNAscope ISH technology with Imaging Mass Cytometry detection to accelerate multiomic interrogation of health and disease. MINNEAPOLIS , May 16, 2023 /PRNewswire/ -- Bio-Techne (NASDAQ: TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities today announced the expansion of the Advanced Cell Diagnostics... Read More

MINNEAPOLIS , May 12, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Jim Hippel , Executive Vice President and Chief Financial Officer, will present at the 2023 RBC Capital Markets Global Healthcare Conference on Tuesday, May 16, 2023 , at 2:35 p.m. EDT . A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at... Read More

MINNEAPOLIS , May 10, 2023 /PRNewswire/ -- Bio-Techne (NASDAQ: TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities today announced the launch of two new RNAscope™ in situ Hybridization Probes Kappa and Lambda as analyte specific reagents (ASRs) for the detection of immunoglobulin kappa and lambda light chains mRNA in B-cells. Detection... Read More

MINNEAPOLIS , May 3, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the third quarter ended March 31, 2023 . Third Quarter FY2023 Highlights Third quarter organic revenue increased by 3% (1% reported) to $294.1 million and 4% (2% reported) in the first nine months of fiscal 2023 to $835.4 million . GAAP earnings per share 1) (EPS) was $0.43 versus $0.37 one year ago.... Read More

MINNEAPOLIS , May 3, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended March 31, 2023 . The quarterly dividend will be payable May 26, 2023 , to all common shareholders of record on May 15, 2023 . Future cash dividends will be considered by the Board of Directors on a quarterly basis. Bio-Techne Corporation... Read More

MINNEAPOLIS , May 2, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth , President and Chief Executive Officer, will present at the BofA Securities 2023 Health Care Conference on Wednesday, May 10, 2023 , at 1:40 p.m. PDT . A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at... Read More

Bringing together Bio-Techne's gold standard RNAscope™ technology with Lunaphore's multiplex sequential immunofluorescence (seqIF™) COMET™ system to develop a best-in-class end-to-end multiomics workflow. MINNEAPOLIS and LAUSANNE, Switzerland , April 17, 2023 /PRNewswire/ -- Bio-Techne (NASDAQ: TECH), a global life sciences... Read More

MINNEAPOLIS , April 13, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced it will present its portfolio of products and solutions to advance cancer research and enable cell and gene therapy development and manufacturing at the upcoming annual meeting of the American Association for Cancer Research (AACR), taking place April 14-19 in Orlando, Florida . Bio-Techne's booth (#1763) will feature its wide... Read More

MINNEAPOLIS , April 12, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Wednesday, May 3, 2023 , at 8:00 a.m. CDT to review third quarter 2023 financial results. Access to the discussion may be obtained as follows: Time: 8:00 a.m. CDT Date: May 3, 2023 Dial-in: 1-877-300-8521 or 1-412-317-6026 (for international callers) Conference ID:... Read More

MINNEAPOLIS , April 5, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced it that it has reached a significant milestone with more than 1,000 Ella™ automated immunoassay instruments now in the field. The achievement is a testament to the growing demand across scientific and clinical research sectors for a fast and efficient immunoassay solution capable of delivering precise, and reliable biomarker... Read More

MINNEAPOLIS , April 3, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced it has completed its investment in Wilson Wolf Manufacturing. Wilson Wolf achieved the trailing 12-month earnings before interest, taxes, depreciation, and amortization (EBITDA) target of $55 million , triggering Bio-Techne's initial investment in the company. Bio-Techne's $257 million investment gives the Company a 20%... Read More

MINNEAPOLIS , March 15, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced it has completed its participation in the Cell and Gene Therapy Catapult Process Analytical Technology (Catapult PAT) consortium, a multi-year collaboration involving 24 partner companies, technology providers, therapy developers, and charities. The Catapult PAT consortium is the first initiative of this scale and functional... Read More

MINNEAPOLIS , March 10, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Jim Hippel , Executive Vice President and Chief Financial Officer, will present at the Barclays Global Healthcare Conference on Tuesday, March 14, 2023 , at 2:35 p.m. EDT . A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at... Read More

MINNEAPOLIS , March 1, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced Wilson Wolf Manufacturing has met the trailing 12-month earnings before interest, taxes, depreciation, and amortization (EBITDA) target of $55 million , triggering Bio-Techne's initial investment in the company, which is expected to close at the end of March 2023 . Bio-Techne's $257 million investment will give the Company a 20%... Read More

MINNEAPOLIS , Feb. 28, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth , President and Chief Executive Officer, will present at the Cowen 43 rd Annual Health Care Conference on Monday, March 6, 2023 , at 2:10 p.m. EST . A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at... Read More

Medicare contractor National Government Services finalizes local coverage determination for biomarker testing related to prostate cancer to include repeat biopsies and yearly testing MINNEAPOLIS , Feb. 24, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that a newly finalized local coverage determination (LCD) from National Government Services, Inc., a Medicare Administrative Contractor, includes... Read More

MINNEAPOLIS , Feb. 22, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Jim Hippel , Executive Vice President and Chief Financial Officer, will present at the Citi 2023 Healthcare Services, Medtech, Tools & HCIT Conference on Wednesday, March 1, 2023 , at 2:00 p.m. EST . A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at... Read More

MINNEAPOLIS , Feb. 14, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) and Cell Signaling Technology (CST) announced today the addition of Simple Western™ validation to CST antibodies. This will allow researchers in various disciplines an easier way to study important molecular signaling pathways on a trusted and validated platform. Obtaining accurate data efficiently and fast is key to advancing drug discovery... Read More

MINNEAPOLIS , Feb. 2, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the second quarter ended December 31, 2022 . Second Quarter FY2023 Highlights Second quarter organic revenue increased by 4% (1% reported) to $271.6 million and 5% (3% reported) in the first half of fiscal 2023 to $541.2 million . GAAP earnings per share 1) (EPS) was $0.31 versus $0.49 one year ago.... Read More

MINNEAPOLIS , Feb. 2, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended December 31, 2022 . The quarterly dividend will be payable February 27, 2023 , to all common shareholders of record on February 13, 2023 . Future cash dividends will be considered by the Board of Directors on a quarterly basis. Bio-Techne... Read More